Research and development
Discovery and optimization for small molecules, peptides, and related modalities.
Small-molecule R&D
We support hit finding, lead optimization, and route scouting with a focus on properties that matter in development: selectivity, ADME risks, and scalable chemistry.
Peptides and peptidomimetics
We design and refine peptide sequences and mimetics with an eye toward potency, stability, and preparation—not just activity on paper.
Analytical rigor
Clear characterization, controlled experiments, and traceable data underpin every recommendation we make. That discipline reduces rework and shortens the path to the next decision.
Hit triage and screening
We help narrow chemical matter so you spend cycles on the most promising scaffolds and series—pairing in vitro readouts, early liability flags, and synthesis feasibility to avoid dead-end scale-up.
Developability
Lead optimization is not just potency. We factor in solubility, permeability, stability, and route robustness as programs mature, so the molecule you love in a vial is closer to the molecule you can develop.
Ecosystem and external work
We can work alongside your in-house team, CROs, and specialists—helping you specify studies, review packages, and integrate data into a single program narrative. If you are peptide-heavy, small-molecule-heavy, or a hybrid, we meet you where the science is.
Translational design and biomarker awareness
Where your program has a defined patient or preclinical path, we align chemistry and peptide design with exposure, PD, and translational endpoints you care about—so series decisions do not ignore how a molecule will be tested in the next species or stage.
Structure-informed and computational input
When structural data, homology models, or affinity data exist, we use them to prioritize chemotypes and reduce dead-end synthesis. We also apply cheminformatics and property filters to keep libraries focused and manufacturable.
Targeted protein degradation and bifunctional R&D
For programs exploring molecular glues, monovalent degraders, or traditional heterobifunctional chimeras, we support warhead, linker, and exit-vector design with a practical eye on cell permeability, stability, and synthetic tractability.
Orthogonal modalities and combination thinking
We are comfortable at the boundary of small molecules, peptides, and biologics-adjacent ideas—where your target or tissue requires a combination of tool compounds, delivery angles, or mechanism stacking. We help you keep the R&D story coherent for external partners and investors.
RNA-targeting and undraggable-target strategies
For programs pursuing small-molecule splicing modulators, RNA binders, or other emerging mechanisms, we align design cycles with the assays and model systems you trust—respecting the higher bar for selectivity and off-target risk in nucleic-adjacent mechanisms.
3D models, organoids, and disease-relevant readouts
We do not run GLP in vivo work in house, but we help you connect chemistry to the right CROs and to complex models—so potency in a biochemical assay does not mislead a program that will live or die in a tissue-specific or patient-derived context.
Portfolio and competitive context
We support IP-aware SAR, freedom-to-operate–sensible scaffolds, and an honest view of how your series sits next to public clinical and preclinical literature—so your R&D and BD narratives stay aligned.
Tech transfer and manufacturing readiness
As programs approach external scale-up, we help with process parameter ranges, impurity and spec expectations, and transfer documentation so your CMO or internal plant receives a package that matches what R&D actually learned—not a last-minute handoff.
Immunogenicity and developability for peptides and conjugates
For therapeutic peptides and bioconjugates, we design with sequence-level and linker-level risk in view, in coordination with your immunogenicity and tox partners—so chemistry does not create avoidable liabilities late in the program.
See how we map to application and disease focus, and concrete service lines on the R&D offerings page. Specific program details are shared under appropriate confidentiality terms. Start a conversation.